Searched for
TARIFFS ON GENERIC MEDICATIONS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Policy clarity helps protect pricing stability, ensure supply: Pharma companiesThe latest move would support pricing stability and supply continuity for one of India's top export items to America, even as both sides co...
- Strengthening the India-US medicines partnership important: IPAThe Indian Pharmaceutical Alliance welcomed an interim trade agreement between India and the US, emphasizing that medicine security is cruc...
- Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster doseThe Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharma companies that supply near...
- Bitter pill, not poison: 100% Trump tariff on imported meds can act as smelling salt for Indian pharmaTrump's 100% tariff on imported branded drugs poses limited immediate threat to Indian pharma, as it excludes generics, India's main US exp...
- Trump delivers another bitter tariff pill. Who’s set to bite the dust?A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unles...
- Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry expertsThe US imposition of a 25% tariff on Indian goods, plus penalties, threatens to increase US healthcare costs, impacting pharmaceutical firm...
- Trump's tariff move on India may backfire, pharma industry leaders sayIndian pharmaceutical industry leaders strongly criticize U.S. President Trump's tariff announcement, arguing it will harm the American hea...
- India-UK FTA prescribes a booster dose for Indian pharma and medtech exportsThe India-UK FTA is poised to significantly boost India's pharmaceutical and medical device sectors. Tariff relief and streamlined regulati...
- Duty relief to boost pharma companies' access to UK drug storesThe India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and strea...
- India-UK FTA: Zero duty to boost India's generic drug, medical device exports to BritainIndia and the UK have signed a free trade agreement. This deal eliminates duties on generic medicines and medical devices. Indian medical d...
- 200% tariffs in offing? Trump vows to slash drug prices using import restrictionsPharma Tariffs: US President Donald Trump plans to impose a 200 percent tariff on imported medicines to push drug companies into cutting pr...
- Trump’s new drug tariffs could hit patients hard - here's a list of essential meds at risk of vanishing fastDonald Trump plans tariffs on pharmaceutical imports, which has led healthcare experts to worry about drug shortages. Common drugs like pai...
- US govt order unlikely to impact on Indian pharma players, says CiplaUmang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are alrea...
- Trump’s executive order on drug pricing could be a booster for Indian pharma industryDonald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generi...
- US tariff threat on Indian generics: What it means for pharmaTariffs on Indian generics could raise US drug prices, disrupt supply chains, and strain insurance systems. Indian firms, reliant on US rev...
- Trump faces pressure from US industry over China tariff on medicinesU.S. hospitals and generic drugmakers are urging President Trump to exempt medical goods from new tariffs on Chinese imports, warning of po...
- India keen to collaborate with East Asian nations to produce generic drugs, vax: Anupriya Patel“India is willing to collaborate with East Asian partners in the production of generic drugs and medical technologies used for treatment of...
Load More
